



**Multimeric Biotherapeutics, Inc.**  
**("Multimeric")**  
***"Unlocking the potential of the TNF SuperFamily Ligands"***

**Multimeric Biotherapeutics, Inc. obtains an exclusive license to highly active forms of the TNF SuperFamily (TNFSF) molecules using the UltraLigand™ multimerization technology**

April 25, 2011, La Jolla, CA – Multimeric Biotherapeutics, Inc. ("Multimeric") announced today that it has obtained an exclusive worldwide license from the University of California San Diego (UCSD) to all therapeutic uses of the UltraLigand™ technology for producing highly active many-trimer molecules from the TNFSF protein family. The technology was invented by Richard S. Kornbluth, M.D., Ph.D. when he was an Associate Professor of Medicine at UCSD. Dr. Kornbluth is now the President and Chief Scientific Officer of Multimeric.

The basis of the technology is the realization that many TNFSF ligands are only active when produced as many-trimer multimers. Of these molecules, the most advanced is a 4-trimer form of CD40 ligand (CD40L), which is widely recognized as the single most powerful immune-stimulating molecule made by the body. This molecule, UltraCD40L™, is formed by fusing the body of surfactant protein D (SP-D) with the receptor-binding domain of CD40L. A related 2-trimer protein, MegaCD40L™, is formed by fusing the body of Acrp30 (adiponectin) with the receptor-binding domain of CD40L. In laboratories around the world, these and related molecules in the UltraLigand™ and MegaLigand™ families have been shown to dramatically enhance vaccine responses ("adjuvant" activity) and induce curative anti-cancer immunity in animal models.

The license includes exclusive rights to issued patents in the U.S. (US 7,300,774 and US 7,332,298) that cover both the UltraLigand™ and MegaLigand™ technologies in the U.S. In addition, the license includes exclusive rights to an issued patent (EP1235853B1) that covers the UltraLigand™ technology in Europe. Also included in the license is a pending patent for immunostimulatory combinations useful for cancer immunotherapy (US 2009/0081157 A1).

**About Multimeric Biotherapeutics, Inc.**

Multimeric Biotherapeutics, Inc. is a privately held, early-stage biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. Its core, patented technology is being used to create next-generation vaccines and tumor immunotherapies. MultimericBio has offices in La Jolla, CA, and laboratories in Carlsbad, CA, both in the San Diego area. More information is available at [www.multimericbio.com](http://www.multimericbio.com) . Contact us at [info@multimericbio.com](mailto:info@multimericbio.com)